In conclusion, we have demonstrated that targeting the pro-HGF activating protease, matriptase, in IBC efficiently inhibits pro-oncogenic c-Met signaling, and that future studies testing potent and highly selective matriptase inhibitors and their potential as novel targeted drugs in IBC as well as TNBC may be a promising new therapeutic strategy. Here, MET is linked to inflammatory breast carcinoma.